Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical ...

Importantly, the Medtronic CoreValve device, as well as a subcoronary anchor point at the aortic annulus, has a supra-coronary anchor point at the outflow of the device. This means the proximal ...

2 Eligible patients had an aortic valve annulus area of ≤430 mm as measured by computed tomography, and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...

Those who were eligible, had an aortic valve annulus area of ≤430mm as per the computed tomography measurements, and “suitable” anatomy for transfemoral TAVR with either an Evolut PRO/PRO+ ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...

2 Eligible patients had an aortic valve annulus area of ≤430 mm as measured by computed tomography, and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 Ultra™ ...

2 Eligible patients had an aortic valve annulus area of ≤430 mm as measured by computed tomography, and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 Ultra™ ...